MARKET COMPOSITE
ELAN - Elanco Animal Health Inc8:00:02 PM 4/25/2024
Price
$13.04
-0.27 (-2.03%)
Elanco Animal Health Incorporated is an American pharmaceutical company which produces medicines and vaccinations for pets and livestock. Until 2019, the company was a subsidiary of Eli Lilly and Company, before being divested. The company can trace its roots back to the mid-1950s when Eli Lilly introduced their first antibiotic aimed at veterinary usage with the new plant and animal sciences research being combined into Lilly's Agro-Industrial division. In the 1960s the Agro-Industrial division was reorganised, launching Elanco Products Company.
Financials
Quarterly financials
(USD)Dec 2023Q/Q
Revenue1B-3%
Gross Profit519MM-
Cost Of Revenue516MM+6%
Operating Income-127MM-88%
Operating Expenses646MM-
Net Income-141MM-87%
R&D79MM-8%
G&A292MM-7%
Amortization138MM-1%
Interest Expense67MM-7%
Stock Chart

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

Stock news

    Launches first-ever tracking site for often-fatal parvovirus outbreaks to Save 1 Million Puppies by 2030 GREENFIELD, IN / ACCESSWIRE / April 23, 2024 / Elanco Animal Health Incorporated (NYSE:ELAN) today unleashed a multi-faceted educational campaign ...

    In this piece, we will take a look at the 13 best low price pharma stocks to invest in. If you want to skip our overview of the pharma industry and want to skip to the five top low price stocks in this list, then you can skip ahead to 5 Best Low Price Pharma […]

    Elanco Animal Health Incorporated (NYSE: ELAN) will announce its first quarter 2024 financial results on Wednesday, May 8, 2024. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance.

    Elanco Animal Health said on Monday that it had appointed two new directors to its board after reaching an agreement with activist investor Ancora Holdings but stopped short of naming a new CEO. The company that makes medicines and vaccinations for pets and livestock said it has added Kathy Turner and Craig Wallace to the board of directors. that it wanted four board seats at Elanco and to replace CEO Jeffrey Simmons over "poor performance."

    Elanco Animal Health Incorporated (NYSE: ELAN) today announced that it has appointed two new independent directors, Kathy Turner and Craig Wallace, to its Board of Directors (the "Board"), effective immediately, expanding the Board to 14 members.

    Investment firm Ancora Holdings has reached an agreement with Elanco Animal Health to add two of its director candidates to the company's board, Bloomberg News reported late on Sunday, citing people with knowledge of the matter. Elanco, which makes medicines and vaccinations for pets and livestock will add Ancora nominees Craig Wallace and Kathy Turner to its board of directors, the report said. However, Elanco CEO Jeff Simmons will retain his position, the report added.

    Elanco Animal Health Inc (NYSE:ELAN), a company specializing in the development, manufacturing, and marketing of products for animal health and production, has reported an insider purchase filed with the SEC.

    NORTHAMPTON, MA / ACCESSWIRE / March 5, 2024 / Elanco Animal Health CEO, Jeff Simmons joins Jim Cramer on Mad Money to discuss the company's commitment to create solutions for farmers and ranchers that can reduce, measure, and monetize greenhouse ...

    Elanco Animal Health (NYSE: ELAN) announced today the appointment of Shiv O'Neill as the company's Executive Vice President, General Counsel and Corporate Secretary. O'Neill will be responsible for the global strategy and operations of the Company's legal team, ethics & compliance organization and ESG efforts.

    Investment firm Ancora Holdings said it is pushing for four board seats at Elanco Animal Health and wants to replace the chief executive at the company that makes medicines and vaccinations for pets and livestock. Ancora nominated the director candidates, including one of the firm's executives, to Elanco's 12-person board and wants to oust CEO Jeffrey Simmons over what the activist investor calls poor performance. Elanco, which was spun out of pharmaceutical company Eli Lilly, is one of the wo...